



ADVITECH ANNOUNCES A MANDATE TO GROUP CRÉA AND ADMINISTRATIVE CHANGES

TSX VENTURE EXCHANGE: AVI

FOR IMMEDIATE RELEASE

QUEBEC – February 3rd, 2006 – To assist the society in its financing program and to further evaluate new marketing opportunities for its products portfolio, Advitech has mandated Group Créa and more specifically Mr René Gosselin MBA, partner of Group Créa. Mr Gosselin has been involved for many years with biotech companies and has a strong background with the financing and the management of such companies. He sits on the board of directors in the sector of health science and biotechnology. The mandate of Mr Gosselin started on January 4th for a non-specified duration.

To help the society in technical and scientific servicing to marketing partners such as Cothera SAS and PhotoMedex (NASDAQ: PHMD) and to launch DermylexTM, the society has renewed the mandate of Mr Jean Rousseau Ph.D. Mr Rousseau has been directly involved in the negotiation process with PhotoMedex and has brought a significant contribution to the development process of technical and scientific documentation requested for the marketing of DermylexTM.

Finally, Mr Denis Villeneuve has resigned as director of the corporation. Mr Claude Livernoche, Chairman of the board of the Corporation, thanks Mr Villeneuve for its contribution as a member of the board of directors of the Corporation.

About Créa

The Créa Group is a multidisciplinary consulting firm offering a complete array of integrated consulting services to assist companies, investors, universities and research centers in the achievement of technologically innovative projects within the industries of life sciences, biotechnology, agro-food and environment. With more than 10 highly qualified scientific and business professionals, the Créa Group team will accomplish feasibility studies, develop business plans, implement strategies as well as propose ways to finance investment projects or company growth. Its professionals are able to craft optimal strategies and transactions targeted towards health sciences and biotechnology industries in order to achieve one's business goals and objectives, maximizing investment returns for the company and its shareholders.

About Advitech

Advitech is a biotechnology company specializing in the development of clinically tested bioactive ingredients for chronic immune-mediated inflammatory diseases (I.M.I.D.), such as psoriasis and inflammatory bowel diseases. Advitech has recently announces marketing agreements for DermylexTM with Cothera SAS and PhotoMedex (NASDAQ: PHMD). Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.

About Dermylex™

Dermylex™ is Advitech's orally administered product for mild to moderate plaque psoriasis. Dermylex™ is based on Advitech's XP-828L, a bioactive ingredient with proven clinical efficacy. On July 5, 2005, the Company reported positive results from its Phase II clinical trial of XP-828L for treating mild to moderate psoriasis. The 112-day, multi-center, double blind, placebo-controlled study, involving 84 patients, confirmed the efficacy and excellent safety profile of XP-828L for treating mild to moderate psoriasis.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Group Créa

René Gosselin, partner
(514) 982 6969, ext. 236
rene.gosselin@groupecrea.com

Advitech Inc.

Renaud Beauchesne, MBA
President and Chief Executive Officer
(418) 686-7498, ext. 228
r.beauchesne@advitech.com
www.advitech.com